

ANNEX II

- A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**

**A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR
BATCH RELEASE**

Name and address of the manufacturers of the biological active substances

Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'aviation
69800 SAINT-PRIEST
FRANCE

Boehringer Ingelheim Animal Health France SCS
Laboratoire Lyon Gerland
254, Rue Marcel Mérieux
69007 LYON
FRANCE

Name and address of the manufacturer responsible for batch release

Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'aviation
69800 SAINT-PRIEST
FRANCE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

C. STATEMENT OF THE MRLs

Not applicable.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Plastic box of 10 bottles of lyophilisate and 10 bottles of solvent
Plastic box of 50 bottles of lyophilisate and 50 bottles of solvent

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Purevax RCP FeLV lyophilisate and solvent for suspension for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Per dose of 1 ml or 0.5 ml:

FHV (F2 strain) $\geq 10^{4.9}$ CCID₅₀
FCV (431 and G1 strains)..... ≥ 2.0 ELISA U.
FPV (PLI IV) $\geq 10^{3.5}$ CCID₅₀
FeLV recombinant canarypox virus (vCP97)..... $\geq 10^{7.2}$ CCID₅₀.

3. PHARMACEUTICAL FORM

Lyophilisate and solvent for suspension for injection.

4. PACKAGE SIZE

Lyophilisate (10 x1 dose) + solvent (10 x1 ml)
Lyophilisate (50 x1 dose) + solvent (50 x1 ml)
Lyophilisate (10 x 1 dose) + solvent (10 x 0.5 ml)
Lyophilisate (50 x 1 dose) + solvent (50 x 0.5 ml)

5. TARGET SPECIES

Cats

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Not applicable.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP (mm/yyyy)
Once reconstituted use immediately.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated.
Protect from light.
Do not freeze.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

16. MARKETING AUTHORISATION NUMBER(S)

Vm 04491/5054

17. MANUFACTURER'S BATCH NUMBER

Lot

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Lyophilisate bottle

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Purevax RCP FeLV

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

1 dose

4. ROUTE(S) OF ADMINISTRATION

SC

5. WITHDRAWAL PERIOD(S)

6. BATCH NUMBER

Lot

7. EXPIRY DATE

EXP (mm/yyyy)

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.



MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Solvent bottle

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Purevax RCP FeLV solvent

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

1 ml or 0.5 ml

4. ROUTE(S) OF ADMINISTRATION

SC

5. WITHDRAWAL PERIOD(S)

6. BATCH NUMBER

Lot

7. EXPIRY DATE

EXP (mm/yyyy)

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only



B. PACKAGE LEAFLET

PACKAGE LEAFLET:
Purevax RCP FeLV lyophilisate and solvent for suspension for injection

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

Manufacturer responsible for the batch release:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
69800 Saint Priest
FRANCE

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Purevax RCP FeLV
Lyophilisate and solvent for suspension for injection.

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Per dose of 1 ml or 0.5 ml:

Lyophilisate:

Active substances:

Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) $\geq 10^{4.9}$ CCID₅₀¹
Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens .. ≥ 2.0 ELISA U.
Attenuated feline panleucopenia virus (PLI IV) $\geq 10^{3.5}$ CCID₅₀¹

Excipient:

Gentamicin, at most.....23 µg

Solvent:

Active substance:

FeLV recombinant canarypox virus (vCP97) $\geq 10^{7.2}$ CCID₅₀¹.

¹ cell culture infective dose 50%.

Lyophilisate: homogeneous beige pellet.

Solvent: clear colourless liquid with presence of cell debris in suspension.

4. INDICATION(S)

Active immunisation of cats aged 8 weeks and older:

- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs,
- against feline panleucopenia to prevent mortality and clinical signs,
- against leukaemia to prevent persistent viraemia and clinical signs of the related disease.

Onsets of immunity:

- Rhinotracheitis, calicivirus and panleucopenia components: 1 week after primary vaccination course.
- Feline leukaemia component : 2 weeks after primary vaccination course.

Duration of immunity:

- Rhinotracheitis, calicivirosis and panleucopenia components: 1 year after primary vaccination course and 3 years after the last re-vaccination.
- Feline Leukaemia component: 1 year after the last re-vaccination.

5. CONTRAINDICATIONS

None.

6. ADVERSE REACTIONS

Transient apathy and anorexia as well as hyperthermia (lasting usually for 1 or 2 days) were commonly observed during safety and field studies. A local reaction (slight pain at palpation, itching or limited oedema) that disappears within 1 or 2 weeks at most was commonly observed during safety and field studies.

Emesis (mostly within 24 to 48 hours) has been observed in very rare cases based on post-marketing safety experience.

A hypersensitivity reaction has been observed uncommonly in field studies,, which may require appropriate symptomatic treatment

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals treated in 100 animals)
- uncommon (more than 1 but less than 10 animals treated in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Cats

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Subcutaneous route.

After reconstitution of the lyophilisate with 0.5 ml or 1 ml of the solvent (depending on the presentation chosen) inject one dose of vaccine according to the following vaccination scheme:

Primary vaccination course:

- first injection: from 8 weeks of age;
- second injection: 3 to 4 weeks later.

Where high levels of maternal antibodies against rhinotracheitis, calicivirosis or panleucopenia components are expected to be present (e.g. in kittens of 9 to 12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.

Revaccination:

- the first revaccination must be carried out for all components one year after the primary vaccination course.

Subsequent revaccinations:

- Feline leukaemia component: every year.
- Rhinotracheitis, calicivirosis and panleucopenia components: at intervals of up to three years.

9. ADVICE ON CORRECT ADMINISTRATION

Reconstitute gently the vaccine in order to obtain a uniform suspension with limited foam formation.

Visual appearance after reconstitution: slightly yellow suspension with presence of cell debris in suspension.

10. WITHDRAWAL PERIOD(S)

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Protect from light.

Do not freeze.

Do not use this veterinary medicinal product after the expiry date, which is stated on the label after EXP

Shelf life after reconstitution according to directions: use immediately.

12. SPECIAL WARNING(S)

Special warnings for each target species:

Vaccinate healthy animals only.

Special precautions for use in animals:

It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination. Vaccination of FeLV positive cats is of no benefit.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

Do not use during the whole pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Boehringer Ingelheim adjuvanted vaccine against rabies.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose (symptoms, emergency procedures, antidotes):

No effect other than those already mentioned in section on "Adverse reactions" have been observed, except hyperthermia that may exceptionally last 5 days.

Incompatibilities:

Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the product.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

15. OTHER INFORMATION

The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the *env* and *gag* genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against sub-group A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat. As a consequence, the vaccine induces an immune status against feline leukaemia virus.

The product was shown to reduce excretion of feline calicivirus at onset of immunity and for one year after vaccination.

Plastic box containing:

10 x 1 dose of lyophilisate and 10 x 1 ml of solvent or
50 x 1 dose of lyophilisate and 50 x 1 ml of solvent or
10 x 1 dose of lyophilisate and 10 x 0.5 ml of solvent or
50 x 1 dose of lyophilisate and 50 x 0.5 ml of solvent.

Not all pack sizes may be marketed.

Approved 06 May 2022

